Sufferers with extensive-stage small cell lung most cancers (ES-SCLC) who have been closely pretreated noticed advantages from therapies with ifinatamab deruxtecan (I-DXd), trial findings have proven.
This improved efficacy was particularly obvious with a 12 milligram per kilogram (mg/kg) dose versus an 8-mg/kg dose, as proven in an interim evaluation of the part 2 IDeate-Lung 01 trial introduced on the 2024 IASLC World Convention on Lung Most cancers.
In depth-stage lung most cancers, based on the American Most cancers Society, has unfold all through the lung, to the opposite lung or to different elements of the physique.
Examine Highlights:
- A better dose of 12 mg/kg of ifinatamab deruxtecan (I-DXd) was related to a considerably larger total response charge in comparison with the 8 mg/kg dose.
- Illness management charges have been over 80% in each remedy teams.
- The outcomes of the IDeate-Lung 01 trial counsel that I-DXd could also be a promising remedy choice for sufferers with closely pretreated ES-SCLC.
At a median follow-up of 14.6 months within the 8-mg/kg arm (46 sufferers) and 15.3 months for the 12-mg/kg dose (42 sufferers), the confirmed total response charge (ORR; sufferers who responded partially or fully to remedy) was 26.1% versus 54.8%, respectively. Within the 8-mg/kg arm, the ORR included one full response (CR, disappearance of most cancers; 2.2%) and 11 partial responses (PRs; a lower in tumor dimension or extent of most cancers within the physique; 23.9%). Within the 12-mg/kg arm, the 54.8% ORR consisted of all PRs.
Nevertheless, the median length of response (DOR) was 7.9 months and 4.2 months within the 8-mg/kg and 12-mg/kg arms, respectively. The illness management charge (DCR; sufferers whose illness disappeared, shrunk or was steady from remedy) was 80.4% and 90.5% within the 8-mg/kg and 12-mg/kg arms, respectively.
“Illness management charges have been glorious, truly, on each arms,” Dr. Charles M. Rudin, a thoracic medical oncologist and deputy director at Memorial Sloan Kettering Most cancers Heart in New York, mentioned throughout an oral presentation of outcomes. “I am going to level to the 12-mg/kg dose with a illness management charge of 90% — actually spectacular, I believe, within the context of recurrent, metastatic, small cell lung most cancers.”
Within the part 2 trial, sufferers with ES-SCLC (88 sufferers) have been randomly assigned to obtain both 8 mg/kg of I-DXd intravenously or 12 mg/kg. Sufferers enrolled within the trial had ES-SCLC and beforehand acquired one to a few traces of remedy, together with platinum-based chemotherapy, had an ECOG efficiency standing of 0 or 1 (which means they have been doubtlessly restricted in strenuous exercise however may carry out each day duties) and had a minimum of one measurable lesion. Sufferers with asymptomatic mind metastases that have been untreated or beforehand untreated have been permitted to enroll.
The first finish level was ORR; secondary finish factors have been DOR and progression-free survival (PFS; the time a affected person lives with out their illness spreading or worsening); total survival (OS; the time a affected person lives, no matter illness standing); DCR; time-to-treatment response; ORR; and security. The info cutoff date was April 25, 2024. Remedy was ongoing in 4 sufferers in every arm.
The median age was 64 years, 71.6% of sufferers have been male, and most sufferers had an ECOG efficiency standing of 1 (78.4%). Forty-two p.c of sufferers had mind metastasis at baseline. Half of sufferers had two prior traces of systemic remedy, and barely greater than half had a chemotherapy-free interval of lower than 90 days. Sufferers acquired both Zepzelca (lurbinectedin; 15.9%), irinotecan or topotecan (35.2%), Imdelltra (tarlatamab; 6.8%) or amrubicin (6.8%) as their choose prior anticancer remedy.
Outcomes confirmed that the confirmed ORR for systemic response was 26.3% and 61.1% within the 8-mg/kg (19 sufferers) and 12-mg/kg (18 sufferers) arms, respectively, for sufferers with mind metastases at baseline. The 26.3% ORR comprised a 5.3% CR charge and a 21.1% PR charge; the steady illness (SD; most cancers that’s neither rising or reducing in severity), progressive illness (PD; most cancers that’s spreading, rising or getting worse) and never evaluable (NE) charges have been 57.9%, 10.5% and 5.3%, respectively. The 61.1% ORR within the 12-mg/kg arm consisted totally of PRs; the SD, PD and NE charges have been 27.8%, 11.1% and 0%, respectively.
Amongst sufferers with mind goal lesions at baseline within the 8-mg/kg (6 sufferers) and 12-mg/kg arms (10 sufferers), the confirmed ORR for systemic response was 16.7% and 60%. The 16.7% ORR consisted of 1 CR; the SD, PD, and NE charges have been 50%, 33.3%, and 0%, respectively. The 60% ORR within the 12-mg/kg arm consisted of all PRs; the SD, PD, and NE charges have been 30%, 10%, and 0%, respectively.
Additionally in these with mind goal lesions, the intracranial confirmed ORR was 66.7% versus 50% in the identical respective arms. The 66.7% ORR had a 33.3% CR charge and a 33.3% PR charge; the SD charge was additionally 33.3%. The 50% ORR consisted of a 20% CR charge and a 30% PR charge; 5 sufferers (50.0%) had SD.
Further findings confirmed that the median PFS was 4.2 months in contrast with 5.5 months within the 8-mg/kg versus 12-mg/kg arms, respectively. The median OS was 9.4 months and 11.8 months, respectively.
Concerning security within the ES-SCLC affected person inhabitants, I-DXd was typically properly tolerated at each doses. The median remedy length was 3.5 months and 4.7 months amongst sufferers within the 8-mg/kg and 12-mg/kg arms. The median variety of remedy cycles have been six and seven.5 within the respective arms.
“We’ve a good bit of expertise with antibody-group conjugates with the deruxtecan payload at this level, and I do not assume there have been any nice surprises right here,” Rudin mentioned through the presentation.
Remedy discontinuations in sufferers from the 8-mg/kg arm have been resulting from grade 3 (extreme) pneumonia (one affected person), grade 2 (reasonable) pneumonitis (irritation of the lung tissue; one affected person), and grade 4 (life-threatening) pulmonary embolism (blood clots; one affected person). Within the 12-mg/kg arm, discontinuations have been resulting from grade 1 (delicate) and grade 3 pneumonia (one affected person every), grade 2 pneumonitis (one affected person), grade 2 interstitial lung illness (scarring of the lungs; one affected person), grade 3 pneumocystis jirovecii pneumonia (fungal an infection within the lungs; one affected person), grade 4 radiation pneumonitis (one affected person), and grade 5 (deadly) septic shock (one affected person).
The most typical any-grade unwanted effects in 10% or extra of the affected person inhabitants receiving 8 mg/kg and 12 mg/kg of I-DXd included nausea (28.3%; 50%), decreased urge for food (17.4%; 42.9%), anemia (13%; 35.7%), decreased neutrophil rely/neutropenia (10.9%; 33.3%), decreased white blood cell rely (4.3%; 21.4%), asthenia (weak spot; 13.0%; 21.4%), infusion-related reactions (6.5%; 14.3%), diarrhea (10.9%; 14.3%), fatigue (13.0%; 14.3%) and vomiting (15.2%; 7.1%).
“Remedy-related [side effects] related to grade 3 and above have been related, a little bit bit larger treatment-emergent [side effects] related to drug discontinuation on the 12-mg/kg dose cohort, maybe associated to longer length of remedy,” Rudin mentioned. “We are able to see that the first hostile impact is absolutely specializing in [gastrointestinal] toxicity and hematologic toxicity, once more, not sudden.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
